News

Sometimes it is best that we don't know what we don't know.

The FDA has cleared for marketing a hand-held spectral-domain ophthalmic imaging system that opens new doors to ophthalmologists to diagnose eye disease in infants, children, and disabled adults.

Philosophical differences abound between managers and physicians.

A trunk show is one of the most productive business strategies to generate revenue, excitement, and buzz for your dispensary.

Planned anisometropia in patients with long-standing diplopia who are undergoing bilateral cataract surgery can be a triple-win situation, providing clear uncorrected vision at both distance and near while simultaneously eliminating or reducing awareness of pre-existing double vision.

The Burke Medical Research Institute has been awarded a 5-year, $2,262,500 scientific research grant by the National Eye Institute of the National Institutes of Health.

The hazards to the eyes of ultraviolet (UV) radiation are well known to eye-care professionals, but it’s possible they’re not conveying the need for UV protection strongly enough to their patients.

Avalanche Biotechnologies Inc. and Lonza have announced a manufacturing collaboration focused on process development and scale-up efforts for the manufacturing of adeno-associated viral (AAV) vectors for gene therapy.

Smartphones can be a big help to the visually impaired, but few eye-care professionals (ECPs) are recommending them to patients, according to the results of a study presented at this year’s annual meeting of the Association for Research in Vision and Ophthalmology.

Bioptigen has received 510(k) clearance from the FDA to begin marketing its hand-held spectral-domain optical coherence tomography (OCT) device (Envisu) for use in patients.

Nidek has received FDA 510(k) clearance for a non-mydriatic automated fundus camera (AFC-330) that it will market to the U.S. ophthalmology market and Marco Ophthalmic will market to the optometry market.

The jury is still out on the effects of anesthesia in children who undergo surgery at a young age, according to Constance S. Houck, MD. Multiple animal studies have demonstrated neuroapoptosis and long-term learning deficits in young animals after administration of general anesthesia, but population-based studies in humans have been far less clear.

Abbott Medical Optics (AMO) has announced an impending change in leadership with the expected retirement of James V. Mazzo, president and chief executive officer (CEO), by the end of this year. Mazzo will be succeeded by Murthy Simhambhatla, PhD, who currently heads the Ibis Biosciences division of AMO’s parent company, Abbott Laboratories.

On April 20, Abbott Medical Optics announced that it had received FDA clearance for use of the 150-kHz iFS advanced femtosecond laser to create arcuate incisions during corneal surgery, including cataract surgery.

Independent medical practices continue to adopt electronic health record technology at an increasing rate.

Understanding the cause of elevated IOP in patients with uveitis is the basis for developing a rational treatment plan.

The premium sunglasses business is very trendy.

Leading refractive surgeons agree wavefront-guided ablation is a significant advance in laser vision correction, but have different opinions about its role in treating myopic eyes with low higher-order aberrations.

A record number of ophthalmologists hit the hallways on Capitol Hill last month to urge their legislators to protect Americans' access to eye care and boost funding for eye research.

The Association for Research in Vision and Ophthalmology closed its 2012 annual meeting with more than 12,500 participants – its largest attendance ever.

Using interferon alpha-2b systemically for the treatment of refractory uveitic cystoid macular edema may be helpful in carefully selected patients.

The corrections following phacoemulsification and IOL implantation that are achievable today are a far cry from those commanded in the 1970s when 20/40 corrected bilaterally was considered an accomplishment following implantation of the early IOLs.

Losing staff is a devastating experience.

As outgoing president of the ASCRS, Edward J. Holland, MD, can be recognized for a number of accomplishments and the introduction of several new initiatives.

As a rule, the latest and greatest new technology first becomes available to the haves in this world, and only much later, if at all, to the have-nots.

Adoption of electronic health record technology has been slow, particularly among ophthalmologists.

Many agents have been investigated in clinical trials for neuroprotection in glaucoma, but none has proven efficacy, and so IOP control continues to be the mainstay strategy for preventing glaucoma progression.

Epimacular brachytherapy was described as "interesting and encouraging" at the 2-year time point for treating exudative age-related macular degeneration that had been previously treated with anti-vascular endothelial growth factor injections.

More than 300,000 proprietary implantable contact lenses (ICLs) of collagen-copolymer material (Visian Implantable Collamer Lens, STAAR Surgical Co.) have been implanted in patients around the world. More than 75,000 have been the toric version of these lenses, approved in all major markets in the world, with the exception of the United States.

A new therapy (Retaine MGD, OCuSOFT) is available for those who have dry eye syndrome and meibomian gland dysfunction.